SEC Filing Summary
Filing identity: The supplied filing is Organovo Holdings, Inc.’s Form 10-K, not a filing for Vivosim Labs, Inc. Investors should verify the issuer before relying on this summary.
Business context and reporting period
Organovo was a development-stage biotechnology company developing 3D-bioprinted human tissues for drug research and testing, with longer-term ambitions in therapeutic implants. This 10-K covers the fiscal year ended March 31, 2014. Because the company changed its fiscal year-end, the filing compares that 12-month year with calendar 2012; the intervening fiscal period ended March 31, 2013 was only three months. These periods are not directly comparable.
Financial performance and position
| Metric | FY ended March 31, 2014 |
|---|---|
| Revenue | $379,000 |
| Operating expenses | $21.0 million |
| Operating loss | $20.649 million |
| Net loss | $25.848 million; $0.35 per share, basic and diluted |
| Research and development expense | $7.974 million |
| Selling, general and administrative expense | $13.054 million |
| Cash used in operating activities | $15.561 million |
| Cash and cash equivalents, March 31, 2014 | $48.167 million |
| Working capital | $47.268 million |
| Total assets / total liabilities | $50.186 million / $1.902 million |
Revenue consisted mainly of collaboration and grant revenue; the company reported no product revenue for FY2014. Product margins therefore are not meaningful for this period. Cash used in investing activities was $268,000, while financing activities provided $48.368 million. Financing included approximately $43.4 million net proceeds from a public offering and $3.5 million from at-the-market sales. Debt was limited in the reported balance sheet: capital lease obligations totaled approximately $15,000; warrant liabilities were $377,000.
Changes versus prior periods
- Revenue declined approximately 67% from $1.197 million in calendar 2012, primarily because earlier collaborations ended or slowed, partly offset by newer collaborations. The periods differ in length alignment and should not be treated as a clean year-over-year comparison.
- Operating expenses rose approximately 100% from $10.5 million in calendar 2012, reflecting increased R&D and commercialization preparation, hiring, public-company costs, facility expansion, and stock compensation.
- Net loss narrowed from $43.553 million in calendar 2012 to $25.848 million in FY2014. The earlier period included substantial noncash warrant and financing charges; FY2014 still included a $5.120 million warrant fair-value expense.
- Cash increased from $15.628 million at March 31, 2013, largely because of equity financing. Working capital rose to $47.268 million from $7.762 million.
Outlook, commentary, and risks
- Management said available cash was sufficient to fund operations for at least 12 months, but additional capital would be needed for further development and commercialization. Future financing was not assured and could dilute shareholders.
- The company expected its first commercial tissue offering to be 3D Human Liver Tissue for toxicology research. In April 2014, after the reporting period, it announced contracts for liver-tissue research services and planned a broader commercial launch before the end of calendar 2014. This was a plan, not a guarantee.
- Management reported research collaborations with pharmaceutical, biotechnology, academic, and other organizations. Revenue and future payments depend on research progress, partner decisions, and any subsequent agreements.
- Key risks include the unproven technology and business model, continued operating losses, uncertain customer adoption, competition, access to human cells and manufacturing capacity, intellectual-property challenges, and potentially lengthy regulation for therapeutic products. Research-use tissue models were not known to require current FDA approval, but therapeutic applications face extensive regulatory review.
- A dispute with Spencer Trask Ventures over warrant-solicitation and placement-agency compensation was in arbitration, scheduled to begin in March 2015. The company recorded no loss accrual because it considered a loss neither probable nor estimable; an unfavorable outcome could materially affect liquidity or financial condition.
- The company reported effective disclosure controls and internal control over financial reporting; its auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Confirm that Organovo Holdings, Inc.—rather than Vivosim Labs, Inc.—is the intended issuer and that March 31, 2014 is the intended reporting period.
- Check subsequent filings for actual liver-tissue launch timing, customer demand, product revenue, and repeat or expanded collaboration agreements.
- Assess cash burn against the $48.167 million year-end cash balance, particularly as commercial and facility costs increase, and review subsequent financing and dilution.
- Review the Spencer Trask arbitration outcome and any later change in the company’s contingency assessment.
- Evaluate whether the company demonstrated reproducible product performance, scalable supply of human cells, customer acceptance, and any required regulatory or quality-system compliance.